Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Filings indexed 3,407 across all filing types
Latest filing 2025-10-28 Board/Management Inform…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director Declaration
Board/Management Information Classification · 100% confidence The document is an announcement from AstraZeneca PLC regarding a change in the board of directors, specifically noting that a Non-Executive Director has been appointed to the board of another company (DexCom, Inc.). This type of disclosure regarding board composition and external appointments falls under the 'Board/Management Information' category.
2025-10-28 English
Koselugo (selumetinib) approved in the EU
Regulatory Filings Classification · 95% confidence The document is a press release issued via the Regulatory News Service (RNS) by AstraZeneca PLC. It announces the European Commission's approval of the drug 'Koselugo' for a specific medical condition. This is a corporate announcement regarding product development and regulatory approval, which falls under the general category of regulatory filings/announcements as it does not fit into specific financial reporting categories like 10-K, IR, or ER.
2025-10-28 English
TEZSPIRE APPROVED IN EU FOR CRSWNP
Regulatory Filings
2025-10-22 English
Tezspire Approved in EU for CRSwNP
Regulatory Filings Classification · 100% confidence The document is a press release from AstraZeneca announcing the European Union approval of the drug 'Tezspire' for a specific medical condition. It follows the standard format of a corporate regulatory announcement (RNS - Regulatory News Service), providing details on the approval, clinical trial results (WAYPOINT), and background information on the drug and collaboration. It does not fit into specific financial reporting categories like 10-K or IR, and it is not a simple report publication announcement as it contains the substantive news itself. Therefore, it is classified as a general regulatory filing.
2025-10-22 English
US FDA APPROVES TEZSPIRE IN CRSWNP
Regulatory Filings
2025-10-20 English
POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO
Regulatory Filings
2025-10-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.